RVL Pharmaceuticals plc Accounts Receivable
RVL Pharmaceuticals plc had Accounts Receivable of $1.00 million as of 2023-06-30, per its 10-Q filed 2023-08-14.
Discontinued › Balance Sheet › Assets › Assets, Current › Receivables, Net, Current › Accounts Receivable, after Allowance for Credit Loss, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2023-08-14
- 2023-06-30: Accounts Receivable, after Allowance for Credit Loss, Current $1.00M.
- 2023-03-31: Accounts Receivable, after Allowance for Credit Loss, Current $9.00K.
- 2022-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $947.00K.
- 2022-09-30: Accounts Receivable, after Allowance for Credit Loss, Current $1.37M.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current | Accounts Receivable, after Allowance for Credit Loss, Current as first filed |
|---|---|---|
| 2023-06-30 | $1.00M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $9.00K 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $947.00K 10-Q · filed 2023-08-14 | |
| 2022-09-30 | $1.37M 10-Q · filed 2022-11-10 | |
| 2021-12-31 | $2.13M 10-K · filed 2022-03-30 | |
| 2021-09-30 | $4.19M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $645.00K 10-Q · filed 2021-08-16 | |
| 2021-03-31 | $22.59M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $3.15M 10-K · filed 2022-03-30 | $26.41M 10-K · filed 2021-03-30 |
| 2020-09-30 | $21.57M 10-Q · filed 2020-11-10 | |
| 2020-06-30 | $17.02M 10-Q · filed 2020-08-11 | |
| 2020-03-31 | $32.64M 10-Q · filed 2020-05-12 | |
| 2019-12-31 | $794.00K 8-K · filed 2021-09-08 | $43.91M 10-K · filed 2020-03-19 |
| 2019-09-30 | $33.86M 10-Q · filed 2019-11-14 | |
| 2019-06-30 | $68.14M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $56.89M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $56.42M 10-K · filed 2020-03-19 | $56.42M 10-K · filed 2019-03-28 |
| 2018-09-30 | $72.72M 10-Q · filed 2018-11-08 | |
| 2017-12-31 | $37.64M 8-K · filed 2019-12-20 |